Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
Trial details
- Registry ID
- NCT05366855
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as ANB019
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPPNCT05366855 | Vanda Pharmaceuticals | Phase 3 | Terminated | 2024-07-12Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |